
Matthew Galsky, MD
Cancer (Oncology)
About Me
Dr. Galsky is Professor of Medicine (Hematology and Medical Oncology), Director of Genitourinary Medical Oncology, Co-Director of the Center of Excellence for Bladder Cancer at The Tisch Cancer Institute, and Associate Director for Translational Research at The Tisch Cancer Institute. Dr. Galsky specializes in the care of patients with genitourinary malignancies—bladder, prostate, kidney, and testicular cancers. His research centers on team science-based approaches to dissecting the mechanistic underpinnings of response and resistance to novel bladder cancer therapies with a particular focus on immunotherapeutic approaches.
Language
Position
Hospital Affiliations
- The Mount Sinai Hospital
About Me
Dr. Galsky is Professor of Medicine (Hematology and Medical Oncology), Director of Genitourinary Medical Oncology, Co-Director of the Center of Excellence for Bladder Cancer at The Tisch Cancer Institute, and Associate Director for Translational Research at The Tisch Cancer Institute. Dr. Galsky specializes in the care of patients with genitourinary malignancies—bladder, prostate, kidney, and testicular cancers. His research centers on team science-based approaches to dissecting the mechanistic underpinnings of response and resistance to novel bladder cancer therapies with a particular focus on immunotherapeutic approaches.
Language
Position
Hospital Affiliations
- The Mount Sinai Hospital
Clinical Focus
- Bladder Cancer
- Kidney Cancer
- Primary Pulmonary Hypertension
- Prostate Cancer
- Testicular Cancer
- Testicular Tumors
- Urologic Cancers
Video
Education
MD, Tufts University
Residency, Internal Medicine
Beth Israel Deaconess Medical Center
Fellowship, Medical Oncology
Memorial Sloan-Kettering Cancer Center
Certifications
American Board of Internal Medicine
Awards
2003
American Society of Clinical Oncology Merit Award
1998
Medical Calss of 1928 Award (Tufts School of Medicine, Excellence in Anatomy)
1998
Leon Levinson Prize (Tufts School of Medicine, Excellence in Physiology)
1997
Alpha Omega Alpha Honor Society
Locations
Insurance Information
Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.
Patients with Cigna Medicare Advantage or Humana Medicare Advantage insurance: Please read this important message before booking to find out if out-of-network costs may apply to your next visit.
- Ruttenberg Treatment Center1470 Madison Avenue, 3rd Floor, New York, NY, 10029
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Publications
Selected Publications
- Sexual Health Outcomes in Sexual Minority and Heterosexual Men After Prostate Radiation Therapy. Daniel R. Dickstein, Thodori Kapouranis, Keith Sigel, Christopher W. Wheldon, Eva Nvepu, Noelle Marie Javier, Robert Stewart, Matthew Galsky, John Sfakianos, Joshua D. Safer, Richard Stock, Karyn Goodman, B. R.Simon Rosser, Kathryn E. Flynn, Deborah C. Marshall. International Journal of Radiation Oncology Biology Physics
- PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting. Mansi Saxena, Thomas U. Marron, Julia Kodysh, John P. Finnigan, Sayali Onkar, Anna Kaminska, Kevin Tuballes, Ruiwei Guo, Rachel Lubong Sabado, Marcia Meseck, Timothy J. O’donnell, Robert P. Sebra, Samir Parekh, Matthew D. Galsky, Ana Blasquez, Gustavo Gimenez, Mesude Bicak, Cansu Cimen Bozkus, Daniela Delbeau-Zagelbaum, Denise Rodriguez, Ana Acuna-Villaorduna, Krzysztof J. Misiukiewicz, Marshall R. Posner, Brett A. Miles, Hanna Y. Irie, Amy Tiersten, Deborah B. Doroshow, Andrea Wolf, John Mandeli, Rachel Brody, Andres M. Salazar, Sacha Gnjatic, Jeff Hammerbacher, Eric Schadt, Philip Friedlander, Alexander Rubinsteyn, Nina Bhardwaj. Cancer Discovery
- Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer. Siamak Daneshmand, Ashish M. Kamat, Neal D. Shore, Joshua J. Meeks, Matthew D. Galsky, Joseph M. Jacob, Michiel S. van der Heijden, Stephen B. Williams, Thomas Powles, Sam S. Chang, James W.F. Catto, Sarah P. Psutka, Félix Guerrero-Ramos, Evanguelos Xylinas, Makito Miyake, Giuseppe Simone, Karen Daniel, Hussein Sweiti, Christopher Cutie, Andrea Necchi. Urologic Oncology: Seminars and Original Investigations
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Galsky during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Aktis
- AbbVie, Inc.
- AstraZeneca
- Seattle Genetics
- Gilead Sciences
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Galsky during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Aktis
- AbbVie, Inc.
- AstraZeneca
- Seattle Genetics
- Gilead Sciences
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.